Latest

amyloid-beta

·November 30, 2022·4 min read

Alzheimer’s Amyloid-Clearing Monoclonal Antibody Drug Lecanemab Shows Positive Results, Poised for FDA Approval

Lecanemab, an amyloid-clearing monoclonal antibody drug shows positive results in the treatment of Alzheimer's disease. The drug is now poised for FDA approval early in 2023. Lecanemab slows cognitive decline by 27%.

Featured Neurology Neuroscience

·November 17, 2022·5 min read

New Target for Alzheimer’s Therapies Found

Researchers have discovered a co-aggregation between amyloid beta and the protein medin in the brains of those with Alzheimer's disease.

Featured Neurology Neuroscience

·November 11, 2022·4 min read

Alzheimer’s Disease Can Be Diagnosed Before Symptoms Emerge

A new study reveals it is not only possible to determine Alzheimer's risks before symptoms appear, but it is also possible to determine who will deteriorate within the next few years.

Featured Neurology Neuroscience

·November 3, 2022·4 min read

The Brain’s Immune Cell Response in Alzheimer’s Disease

Deletion of the neurodegenerative disease associated microglial gene CX3CR1 aggravated the disease state and increased the accumulation of plaques in the brains of mouse models of Alzheimer's disease. Deficiencies of the gene also impaired the movement of microglia toward the plaques.

Featured Neurology Neuroscience

·October 24, 2022·4 min read

Oxytocin Derivative Improves Cognitive Impairment in Alzheimer’s

An intranasally delivered oxytocin derivative helped improve cognitive function and reduced cognitive impairment in mouse models of Alzheimer's disease.

Featured Genetics Neurology Neuroscience

·October 17, 2022·3 min read

A New Protein That May Contribute to Alzheimer’s Disease Identified

The GM2A protein reduces neural firing and induces a loss of neurite integrity.

Featured Neurology Neuroscience

·October 9, 2022·4 min read

Detecting Alzheimer’s Disease in the Blood

A new blood sample test is capable of measuring the build-up of Alzheimer's disease-associated amyloid-beta in the brain.

Featured Neurology Neuroscience

·September 27, 2022·4 min read

New Model of Alzheimer’s as an Autoimmune Disease

Researchers propose a new model for Alzheimer's disease (AD2) that considers the neurodegenerative disease as an autoimmune disease that attacks the brain. Considering Alzheimer's as an autoimmune disorder could spark a new line of therapies to treat the disease.

Featured Neurology Neuroscience

·August 17, 2022·4 min read

How DDT Exposure Contributes to Alzheimer’s Disease Risk

DDT exposure causes sodium channels to remain open, leading to increased neural firing and an increased release of amyloid beta peptide. Blocking the channels with tetrodotoxin reduces the toxic amyloid protein by increasing the production of the amyloid precursor protein.

Featured Neurology Neuroscience

·August 11, 2022·6 min read

Researchers Explore the “Dark Side” of Alzheimer’s Disease Revealing New Biomarkers

A new collection of articles explores mapping brain overexcitability that underpins the dysregulation of vigilance, sleep-wake cycles, and validating effective biomarkers for Alzheimer's disease.

Featured Neurology Neuroscience

·August 1, 2022·6 min read

Is Everything We Think We Know About Alzheimer’s Wrong?

Recent scandals in Alzheimer's research and problems with medications designed to help those with Alzheimer's but failing to deliver sufficient results have researchers questioning the overwhelming focus on amyloid-beta in Alzheimer's research.